StuderUE, WhelanP, WimpissingerF, et al.. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up. Eur Urol2014;66:829–838.
StuderUE, WhelanP, WimpissingerF, . Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up. Eur Urol 2014;66:829–838.10.1016/j.eururo.2013.07.02423932338)| false
Bill-AxelsonA, HolmbergL, GarmoH, . Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370:932–942.2459786610.1056/NEJMoa1311593)| false
MohlerJL, AntonarakisES, ArmstrongAJ, et al.. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1.2019. Accessed March 12, 2019. To view the most recent version of these guidelines, visit NCCN.org.
7.
BernardB, MuralidharV, ChenYH, et al.. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer2017;123:1536–1544.
BernardB, MuralidharV, ChenYH, . Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer 2017;123:1536–1544.2805510810.1002/cncr.30503)| false
AkazaH, UmbasR, Ha ChungB, et al.. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) – Asia Consensus Statement: Prostate Cancer. Version 2.2013. Available at NCCN.org. Accessed March 12, 2019.
9.
AkazaH, HommaY, UsamiM, et al.. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int2006;98:573–579.
AkazaH, HommaY, UsamiM, . Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int 2006;98:573–579.10.1111/j.1464-410X.2006.06349.x16925756)| false
HaUS, ChoiJB, ShimJI, et al.. Is primary androgen deprivation therapy a suitable option for Asian patients with prostate cancer compared with radical prostatectomy?J Natl Compr Canc Netw2019;17:441–449.
HaUS, ChoiJB, ShimJI, . Is primary androgen deprivation therapy a suitable option for Asian patients with prostate cancer compared with radical prostatectomy?J Natl Compr Canc Netw 2019;17:441–449.10.6004/jnccn.2018.726531085754)| false
